Vitality Biopharma Advisor to Present at 11th National Clinical Conference on Cannabis Therapeutics

–Company’s newest advisor a leading investigator into use of medical cannabis for complex pain LOS ANGELES, CA – (May 17, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious...

Vitality Biopharma Announces Positive Results for Cannabinoid Antibiotics

— Antimicrobial activity towards “superbug” pathogens highlights new use for Vitality’s gut-targeted cannabinoid pharmaceuticals LOS ANGELES, CA – (May 10, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and...

Vitality Biopharma Adds Key Clinical Advisors in Gastroenterology

— Company advisors to assist in development of gut-targeted cannabinoid pharmaceuticals for treatment of digestive disorders LOS ANGELES, CA – (May 3, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment...

Vitality Biopharma Releases Clinical Report of Cannabinoid Therapy for Pediatric IBD

— Cannabinoid therapy was able to successfully induce and maintain long-term remission in case study of drug-resistant pediatric inflammatory bowel disease LOS ANGELES, CA – (April 20, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power...

Vitality Biopharma Appoints Pharma Industry Veteran to Advance Cannabosides Regulatory Development

-Prior experience includes Shire Pharmaceutical’s approval of gut-targeted LIALDA™ with MMX® technology for treatment of inflammatory bowel disease LOS ANGELES, CA – (April 12, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment...

Vitality Biopharma Announces International Patent Filing for Neural Repair Treatments

Patent rights assigned to Vitality were based on discoveries made by the Myelin Repair Foundation, a non-profit dedicated to multiple sclerosis research LOS ANGELES, CA – (April 5, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of...

Vitality Biopharma Announces Positive Results for Colon Cancer

Cannabidiol inhibits the growth of colon cancer cell lines, highlights new use for targeted cannabinoid prodrug delivery system LOS ANGELES, CA – (March 30, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment...

The Overlooked Role of Cannabis Drug Manufacturing

Over the last six months, Vitality Biopharma has made a number of breakthroughs enabling us to develop a proprietary new class of cannabinoid pharmaceuticals, file for international patent protection covering these compounds, obtain DEA approval for our research facilities, and most recently to announce our production of novel varieties of THC that have eliminated psychoactivity....

Vitality Biopharma Announces Proprietary THC Pharmaceutical with Greatly Decreased Psychoactivity

Newly developed compounds limit psychoactivity and cognitive impairment and may be especially useful for pediatric applications LOS ANGELES, CA–(Mar 2, 2017) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological and...

Vitality Biopharma to Present at SeeThruEquity 3rd Annual Innovations Investor Conference in Miami

LOS ANGELES, CA–(Feb 16, 2017) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise there will be a corporate presentation at the...